

08 September 2025

Treatments for Multiple Myeloma

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

20 Multiple Myeloma patients received 1st Treatment in BHSCT 01.03.25 to 31.08.25

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

It will unfortunately take longer than 18hours to locate, retrieve, and extract this information.

This would be a manual task and require longer than 18hours to validate as it is Haematology Patients so therefore not on RISOH and we can't use Epic as this would only give number of patients receiving individual drugs, but won't give info on combination or link to diagnosis. This would exceed the costs limit specified in the FOI act.

We estimate that compliance with this element of the request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

- Any other systemic anti-cancer therapy
- Belantamab Mafodotin [Blenrep]
- Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone
- Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone
- Bortezomib [Velcade] monotherapy or with dexamethasone
- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
- Bortezomib, thalidomide and dexamethasone [VTD]
- Carfilzomib [Kyprolis] and dexamethasone
- Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
- Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
- Daratumumab [Darzalex] monotherapy
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)

08 September 2025

- Elranatamab
- Idecabtagene vicleucel [Abecma]
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone
(known as IsaPd)
- Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as
IRd)
- Lenalidomide [Revlimid] and dexamethasone
- Lenalidomide [Revlmid] monotherapy
- Panobinostat in combination with Bortezomib and Dexamethasone
- Pomalidomide [Imnovid] and dexamethasone
- Selinexor and dexamethasone
- Selinexor, Bortezomiv [Velcade] and dexamethasone
- Talquetamab
- Teclistamab [Tecvayli]